Associate Vice President, Clinical Research, Eli Lilly Canada; Clinical Research Physician, Canada and Intercontinental region, Eli Lilly and Company. Adjunct Professor of Psychiatry, Memorial University of Newfoundland, Canada.
Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain
Article first published online: 13 MAR 2008
Copyright © 2008 John Wiley & Sons, Ltd.
Human Psychopharmacology: Clinical and Experimental
Volume 23, Issue 4, pages 275–281, June 2008
How to Cite
Karagianis, J., Hoffmann, V. P., Arranz, B., Treuer, T., Maguire, G. A., de Haan, L. and Chawla, B. (2008), Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain. Hum. Psychopharmacol. Clin. Exp., 23: 275–281. doi: 10.1002/hup.933
- Issue published online: 22 MAY 2008
- Article first published online: 13 MAR 2008
- Manuscript Accepted: 22 JAN 2008
- Manuscript Received: 5 SEP 2007
- atypical antipsychotic;
Several papers and communications have reported possible weight reduction or less weight gain when patients start or switch to orally disintegrating olanzapine, as contrasted with standard oral olanzapine tablets. In this paper, the current literature is reviewed and hypothesized mechanisms of action are discussed. The data are still preliminary and mechanisms of action are not well understood. Randomized controlled trials are needed to further evaluate change in weight during treatment with orally disintegrating olanzapine. Copyright © 2008 John Wiley & Sons, Ltd.